How can health care be improved for Medicare beneficiaries?
Monitoring Medicare beneficiaries’ health care programs
Challenge
How do you ensure that American seniors are getting high-quality care under Medicare, the country’s largest health insurance program? The Centers for Medicare & Medicaid Services (CMS) established the Quality Improvement Organization (QIO) Program to improve the effectiveness, efficiency, economy, and quality of services delivered to Medicare beneficiaries.
Westat, in collaboration with partner Avar, is monitoring the implementation of the QIO Program to ensure it is effective in achieving established goals and protecting both Medicare beneficiaries and the Medicare trust fund.
Solution
Westat is supporting CMS by providing oversight and evaluation of the Beneficiary and Family Centered Care (BFCC) QIO Program. Initiatives include
- Ensuring beneficiary case reviews are efficient, systematic, and thorough
- Using national data to identify areas for quality improvement and increased patient safety
- Collaborating with CMS and other partners to support the rights and services for Medicare beneficiaries
- Engaging beneficiaries and their families to improve how health care is delivered
- Raising awareness about beneficiary rights under the Medicare program
Results
Westat ensures consistent program implementation across the nation and identifies improvements aimed at making CMS services more beneficiary- and family-centered.
Focus Areas
Behavioral Health Health Services Research and Health PolicyCapabilities
Evaluation and Mixed-Methods Research Impact Evaluation Implementation EvaluationSenior Expert Contact
Stephanie J. Fry
Associate Vice President
-
Expert Interview
Safeguarding Data Privacy: Innovations at WestatOctober 2025
Protecting the privacy of people who respond to surveys and censuses is a critical responsibility in federal data collection. During the 2010 Decennial Census, the…
-
Expert Interview
Novel Strategies Transform Clinical Trials Into Future OpportunitiesOctober 2025
For the rigorous evaluation of novel medicines, clinical trials are essential to ensure safety and efficacy. However, clinical trials are experiencing turbulent times due to…
-
Expert Interview
Real-World Insights: Nirsevimab’s Protection Against RSV in InfantsSeptember 2025
Each year in the U.S., respiratory syncytial virus, commonly known as RSV, leads to approximately 58,000 to 80,000 hospitalizations among children under age 5. The…